Key result
Using cardiac troponin to define type-4a peri-procedural myocardial infarction yielded a 9.8% incidence, compared to 4.4% with CK-MB mass, and type-4a MI was not associated with cardiac mortality.
Why the study?
Does the choice of cardiac biomarker and MI definition affect the reported incidence of peri-procedural myocardial infarction in patients undergoing PCI?
RCT (n=2,292)
Does the choice of cardiac biomarker and MI definition affect the reported incidence of peri-procedural myocardial infarction in patients undergoing PCI?
Answers are grounded in this paper and cite their sources.
The reported incidence of peri-procedural MI varies significantly depending on the biomarker used, and type-4a MI may not be a reliable predictor of cardiac mortality or a suitable composite endpoint component in ACS trials.
OBJECTIVE: To assess the differential implications of cardiac biomarker type on peri-procedural myocardial infarction (PMI) reporting. SETTING: The Resolute 'All-Comers' stent trial. INTERVENTIONS: Blood samples for creatine kinase (CK), CK-myoband (CK-MB) mass or cardiac troponin (cTn) (optional) were collected before and at 6, 12 and 18 h after the assigned percutaneous coronary intervention or at discharge. PMIs were adjudicated using either the 2007 universal definition of MI (type-4a) or the extended historical definition of MI. PATIENTS: 2121/2292 patients (92.5%) had an analysable dataset for either biomarker. 890/2121 patients (42%) presented with an acute coronary syndrome (ACS). 267/890 patients (30%) were within 24 h of an ST-segment elevation MI. MAIN OUTCOME MEASURES: Type-4a MI was diagnosed in 208/2121 patients (9.8%) when cTn was used (CK-MB mass if cTn not available), and in 93/2121 of patients (4.4%) when CK-MB mass was used (cTn if CK-MB mass not available). With the extended historical CK-based definition of MI, PMI was diagnosed in 65/2121 patients (3.1%). Adjudication of type-4a MI in patients with an ACS was problematic with <10% of the potential type-4a MI being confirmed as an event, as compared with approximately 95% in stable patients undergoing elective PCI. Type-4a MI was not associated with the subsequent hazard for cardiac mortality (p=0.6). CONCLUSIONS: The percentage of adjudicated PMI events is driven by the MI-definition criteria and biomarker type. Type-4a MI may not be a reliable component of the primary composite end point in coronary stent investigations which recruit patients with ACS. TRIAL REGISTRATION NUMBER: http://www.ClinicalTrials.gov; Unique identifier: NCT00617084.
No takes yet. Share an insight, caveat, or question.
Vranckx et al. (2012) conducted an RCT in Percutaneous coronary intervention (n=2,292). Cardiac troponin (cTn) biomarker definition vs. CK-MB mass or extended historical CK-based definition was evaluated on Diagnosis of type-4a peri-procedural myocardial infarction. Using cardiac troponin to define type-4a peri-procedural myocardial infarction yielded a 9.8% incidence, compared to 4.4% with CK-MB mass, and type-4a MI was not associated with cardiac mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: